THE SOUTH AFRICAN
DEPRESSION AND ANXIETY
GROUP

facebooktwitter

Contact A Counsellor

counsellor button

KNOW MORE

panic anxiety icon

panic anxiety icon

IN THE WORKPLACE

Research on Depression in the Workplace.

For more information please click here

business

SADAG NEWSLETTER

email subscribers list

To subscribe to SADAG's newsletter, click here

To view previous newsletters - click here

MHM JOURNAL

Mental Health Matters Journal for Psychiatrists & GP's

MHM Volume 7 Issue1 small

Click here for more info

JOURNALISTS

journalists crew making newspaper

If you are a journalist writing a story contact Cassey or Kayla or Tracy on 011 234 4837 office@anxiety.org.za

SPEAKING BOOKS

cope with cancer book

Literacy is a luxury that many of us take for granted. That is why SADAG created SPEAKING BOOKS and revolutionized the way healthcare information is delivered to low literacy communities.

The customizable 16-page book, read by local celebrity audio recordings, ensures that vital health and social messages can be seen, heard, read and understood by everyone across the world.

We started with books on Teen Suicide prevention , HIV, AIDS and Depression, Understanding Mental Health and have developed over 100+ titles, such as TB, Malaria, Polio, Vaccines for over 45 countries.

suicide speaking book

Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J
J Am Acad Child Adolesc Psychiatry. 2006;45:408-414

Summary

To estimate the rate of misuse of medications prescribed for attention-deficit/hyperactivity disorder (ADHD), 7 relevant questions were posed to 55 subjects with ADHD (82% male, mean age 20.8 years) and to 43 controls (47% male, mean age 23 years) receiving psychotropic drugs for non-ADHD treatment at 10-year follow-up during a longitudinal case-control study. Four of the yes-or-no questions inquired about using medication for euphoria or selling medication during the 4 preceding years. Among subjects with ADHD, 96% were taking stimulants and 31% were taking serotonin reuptake inhibitors (SRIs); among the controls, 10% were taking stimulants and 80% were taking SRIs. A few subjects in each group were taking antipsychotics, benzodiazepines, or other psychotropics.

The absolute number of subjects reporting misuse or sale of medication was small. On each of the 7 questions, more subjects with ADHD affirmed such behaviors than did controls, but only for selling medication was the difference statistically significant (11% vs 0%, P < .05). Among ADHD subjects who had misused or sold medication, 31% had conduct disorder and 53% had a substance-use disorder; among those who sold medication, all had such a comorbid diagnosis. The medication most often misused or diverted was immediate-release methylphenidate, followed by immediate-release mixed amphetamine salts. Only 10% of subjects had received extended-release stimulant medication, none of whom reported having misused or sold it.

Viewpoint

The major shortcoming of the study is reliance on self-report using an unvalidated instrument. Of those who improperly used medication, 31% had conduct disorder, a criterion of which is lying. Presumably, some proportion of those who denied improper use also had conduct disorder. Recall bias is a given in retrospective reports and, in this case, the reliability of responses is even more in question. Hence, the estimate is likely low. The researchers, however, say that their findings are similar to previous estimates. They also point out that their sample size was predominantly white and middle class and, therefore, not representative of all clinical populations. In addition, the control subjects, none of whom had ADHD, took medications less liable to abuse and diversion, which should be noted in interpreting the results. Nonetheless, the fact that a large proportion of subjects who improperly used their stimulants had conduct disorder or a substance-use disorder is an important finding for clinicians to note.

 

Our Sponsors

Our Partners